Humana (HUM) Financials

$251.91 -4.78 (-1.86%)

Closing price 03:59 PM Eastern

Extended Trading

$251.90 -0.01 (0.00%)

As of 07:55 PM Eastern

Annual Income Statements for Humana

This table shows Humana's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	1,276	614	2,448	1,683	2,707	3,367	2,933	2,806	2,489	1,207
Consolidated Net Income / (Loss)	1,276	614	2,448	1,683	2,707	3,367	2,934	2,802	2,484	1,214
Net Income / (Loss) Continuing Operations	1,276	614	2,448	1,683	2,707	3,367	2,934	2,802	2,484	1,214
Total Pre-Tax Income	2,431	1,552	4,020	2,063	3,456	4,600	3,354	3,568	3,383	1,721
Total Operating Income	2,347	1,741	4,262	3,100	3,192	4,986	3,148	3,800	4,013	2,562
Total Gross Profit	10,020	9,372	10,271	11,030	11,031	15,527	13,865	17,180	17,980	17,097
Total Revenue	54,289	54,379	53,767	56,912	64,888	77,155	83,064	92,870	106,374	117,761
Operating Revenue	54,289	54,379	53,767	56,912	64,387	76,001	82,877	92,488	105,305	116,535
Other Revenue	-	-	-	-	-	1,154	187	382	1,069	1,226
Total Cost of Revenue	44,269	45,007	43,496	45,882	53,857	61,628	69,199	75,690	88,394	100,664
Operating Cost of Revenue	44,269	45,007	43,496	45,882	53,857	61,628	69,199	75,690	88,394	100,664
Total Operating Expenses	7,673	7,631	6,009	7,930	7,839	10,541	10,717	13,380	13,967	14,535
Selling, General & Admin Expense	7,295	7,173	6,567	7,525	7,381	10,052	10,121	12,671	13,188	13,696
Depreciation Expense	355	354	378	405	458	489	596	709	779	839
Total Other Income / (Expense), net	84	-189	-242	-1,037	264	-386	206	-232	-630	-841
Interest Expense	186	189	242	218	242	283	326	401	493	660
Other Income / (Expense), net	270	0.00	0.00	-819	506	-103	532	169	-137	-181
Income Tax Expense	1,155	938	1,572	391	763	1,307	485	762	836	413
Other Gains / (Losses), net	-	-	0.00	11	14	74	65	-4.00	-63	-94
Net Income / (Loss) Attributable to Noncontrolling Interest	-	-	-	-	0.00	0.00	1.00	-4.00	-5.00	7.00
Basic Earnings per Share	$8.54	$4.11	$16.94	$12.24	$20.20	$25.47	$22.79	$22.20	$20.09	$10.01
Weighted Average Basic Shares Outstanding	149.46M	149.38M	144.49M	137.49M	132.11M	128.86M	126.63M	124.97M	120.65M	120.64M
Diluted Earnings per Share	$8.44	$4.07	$16.81	$12.16	$20.10	$25.31	$22.67	$22.08	$20.00	$9.98
Weighted Average Diluted Shares Outstanding	149.46M	149.38M	144.49M	137.49M	132.11M	128.86M	126.63M	124.97M	120.65M	120.64M
Weighted Average Basic & Diluted Shares Outstanding	149.46M	149.38M	144.49M	137.49M	132.11M	128.86M	126.63M	124.97M	120.65M	120.64M
Cash Dividends to Common per Share	$1.14	$1.16	$1.49	$1.90	$2.15	$2.43	$2.73	$3.06	$3.44	$3.54

This table shows Humana's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025
Net Income / (Loss) Attributable to Common Shareholders	1,195	-15	1,239	959	832	-541	741	679	480	-693	1,244
Consolidated Net Income / (Loss)	1,193	-18	1,238	956	830	-540	739	678	480	-683	1,242
Net Income / (Loss) Continuing Operations	1,193	-18	1,238	956	830	-540	739	678	480	-683	1,242
Total Pre-Tax Income	1,297	-71	1,614	1,262	1,098	-591	1,014	918	651	-862	1,691
Total Operating Income	1,172	124	1,719	1,436	1,206	-348	1,236	1,141	728	-543	2,014
Total Gross Profit	4,415	3,857	4,884	4,738	4,678	3,680	4,487	4,501	4,277	3,832	5,577
Total Revenue	22,799	22,439	26,742	26,747	26,423	26,462	29,611	29,540	29,397	29,213	32,112
Operating Revenue	22,627	22,279	26,549	26,473	26,115	26,168	29,323	29,242	29,054	28,916	31,848
Other Revenue	172	-	193	274	308	294	288	298	343	297	264
Total Cost of Revenue	18,384	18,582	21,858	22,009	21,745	22,782	25,124	25,039	25,120	25,381	26,535
Operating Cost of Revenue	18,384	18,582	21,858	22,009	21,745	22,782	25,124	25,039	25,120	25,381	26,535
Total Operating Expenses	3,243	3,733	3,165	3,302	3,472	4,028	3,251	3,360	3,549	4,375	3,563
Selling, General & Admin Expense	3,061	3,551	2,979	3,111	3,271	3,827	3,042	3,148	3,339	4,167	3,380
Depreciation Expense	182	182	186	191	201	201	209	212	210	208	183
Total Other Income / (Expense), net	125	-195	-105	-174	-108	-243	-222	-223	-77	-319	-323
Interest Expense	102	108	113	120	114	146	159	168	169	164	160
Other Income / (Expense), net	227	-87	8.00	-54	6.00	-97	-63	-55	92	-155	-163
Income Tax Expense	107	-58	359	296	256	-75	251	223	155	-216	406
Other Gains / (Losses), net	3.00	-5.00	-17	-10	-12	-24	-24	-17	-16	-37	-43
Net Income / (Loss) Attributable to Noncontrolling Interest	-2.00	-3.00	-1.00	-3.00	-2.00	1.00	-2.00	-1.00	0.00	10	-2.00
Basic Earnings per Share	$9.45	($0.07)	$9.91	$7.70	$6.74	($4.26)	$6.13	$5.63	$3.99	($5.74)	$10.31
Weighted Average Basic Shares Outstanding	126.60M	124.97M	124.94M	123.91M	123.11M	120.65M	120.50M	120.40M	120.41M	120.64M	120.69M
Diluted Earnings per Share	$9.39	($0.08)	$9.87	$7.66	$6.71	($4.24)	$6.11	$5.62	$3.98	($5.73)	$10.30
Weighted Average Diluted Shares Outstanding	126.60M	124.97M	124.94M	123.91M	123.11M	120.65M	120.50M	120.40M	120.41M	120.64M	120.69M
Weighted Average Basic & Diluted Shares Outstanding	126.60M	124.97M	124.94M	123.91M	123.11M	120.65M	120.50M	120.40M	120.41M	120.64M	120.69M

This table details how cash moves in and out of Humana's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Change in Cash & Equivalents	636	1,306	165	-1,699	1,711	619	-1,279	1,667	-367	-2,473
Net Cash From Operating Activities	868	1,936	4,051	2,173	5,284	5,639	2,262	4,587	3,981	2,966
Net Cash From Continuing Operating Activities	868	1,936	4,051	2,173	5,284	5,639	2,262	4,587	3,981	2,966
Net Income / (Loss) Continuing Operations	1,276	614	2,448	1,683	2,707	3,367	2,934	2,802	2,484	1,214
Consolidated Net Income / (Loss)	1,276	614	2,448	1,683	2,707	3,367	2,934	2,802	2,484	1,214
Depreciation Expense	354	388	410	444	505	528	640	749	850	908
Amortization Expense	93	77	75	90	70	88	73	96	67	60
Non-Cash Adjustments To Reconcile Net Income	-246	58	241	822	51	-731	-884	436	553	714
Changes in Operating Assets and Liabilities, net	-609	799	877	-866	1,951	2,387	-501	504	27	70
Net Cash From Investing Activities	320	-1,362	-2,941	-3,087	-1,278	-3,065	-6,556	-1,006	-3,492	-2,952
Net Cash From Continuing Investing Activities	320	-1,362	-2,941	-3,087	-1,278	-3,065	-6,556	-1,006	-3,492	-2,952
Purchase of Property, Plant & Equipment	-523	-527	-524	-612	-736	-964	-1,342	-1,137	-1,004	-575
Acquisitions	-38	-7.00	-31	-2,254	0.00	-709	-4,187	-337	-233	-89
Purchase of Investments	-6,739	-6,566	-6,265	-4,687	-6,361	-9,125	-7,197	-6,049	-7,552	-8,603
Sale of Property, Plant & Equipment	1.00	-	-	-	-	-	26	17	210	7.00
Divestitures	1,061	0.00	0.00	-	-	0.00	0.00	2,701	0.00	0.00
Sale and/or Maturity of Investments	6,558	5,738	3,879	4,466	5,819	7,733	6,144	3,799	5,087	6,358
Other Investing Activities, net	-	-	-	-	-	-	-	0.00	0.00	-50
Net Cash From Financing Activities	-552	732	-945	-785	-2,295	-1,955	3,015	-1,914	-856	-2,487
Net Cash From Continuing Financing Activities	-552	732	-945	-785	-2,295	-1,955	3,015	-1,914	-856	-2,487
Repayment of Debt	298	-2.00	-953	-350	-1,410	-1,056	-1,736	-3,373	-2,379	-2,129
Repurchase of Common Equity	-385	-104	-3,365	-1,090	-1,070	-1,820	-79	-2,096	-1,573	-817
Payment of Dividends	-172	-177	-220	-265	-291	-323	-354	-392	-431	-431
Issuance of Debt	0.00	0.00	1,779	1,485	987	2,088	5,484	1,982	2,644	2,232
Other Financing Activities, net	-293	1,015	1,814	-565	-511	-844	-300	1,965	883	-1,342
Cash Interest Paid	187	185	216	195	212	258	285	354	394	584
Cash Income Taxes Paid	1,179	916	1,498	631	518	1,132	227	758	997	570

This table details how cash moves in and out of Humana's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025
Net Change in Cash & Equivalents	8,338	-8,497	8,674	2,479	-1,066	-10,454	1,216	-409	-385	-2,895	2,029
Net Cash From Operating Activities	8,453	-5,127	6,687	3,176	1,252	-7,134	423	1,213	1,858	-528	331
Net Cash From Continuing Operating Activities	8,453	-5,127	6,687	3,176	1,252	-7,134	423	1,213	1,858	-528	331
Net Income / (Loss) Continuing Operations	1,193	-18	1,238	956	830	-540	739	678	480	-683	1,242
Consolidated Net Income / (Loss)	1,193	-18	1,238	956	830	-540	739	678	480	-683	1,242
Depreciation Expense	186	194	200	210	218	222	226	228	228	226	200
Amortization Expense	28	23	18	16	17	16	16	15	15	14	15
Non-Cash Adjustments To Reconcile Net Income	-170	224	115	7,138	-6,992	292	101	127	101	385	99
Changes in Operating Assets and Liabilities, net	7,216	-5,550	5,116	-5,144	7,179	-7,124	-659	165	1,034	-470	-1,225
Net Cash From Investing Activities	1,676	-1,012	-1,292	-733	-585	-882	-414	-1,002	-1,473	-63	314
Net Cash From Continuing Investing Activities	1,676	-1,012	-1,292	-733	-585	-882	-414	-1,002	-1,473	-63	314
Purchase of Property, Plant & Equipment	-288	-275	-223	-264	-234	-283	-177	-114	-130	-154	-95
Acquisitions	-126	-44	-73	-116	-34	-10	-14	-3.00	-20	-52	0.00
Purchase of Investments	-1,501	-1,309	-1,313	-1,424	-629	-4,186	-1,259	-1,703	-3,441	-2,200	-1,002
Sale and/or Maturity of Investments	883	606	317	1,071	312	3,387	1,036	818	2,118	2,386	1,411
Net Cash From Financing Activities	-1,791	-2,358	3,279	36	-1,733	-2,438	1,207	-620	-770	-2,304	1,384
Net Cash From Continuing Financing Activities	-1,791	-2,358	3,279	36	-1,733	-2,438	1,207	-620	-770	-2,304	1,384
Repayment of Debt	-2,244	-698	-847	112	-5.00	-1,639	-678	-272	261	-1,440	-19
Repurchase of Common Equity	-4.00	-1,064	-94	-529	-379	-571	-717	-49	-2.00	-49	-9.00
Payment of Dividends	-100	-101	-100	-111	-109	-111	-109	-107	-107	-108	-108
Issuance of Debt	-	1,238	1,215	-	-	1,429	2,232	-	-	-	1,481
Other Financing Activities, net	557	-1,733	3,105	564	-1,240	-1,546	479	-192	-922	-707	39
Cash Interest Paid	85	98	97	78	142	77	158	92	166	168	143
Cash Income Taxes Paid	378	7.00	6.00	675	276	40	1.00	361	208	-	-12

This table presents Humana's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Total Assets	24,678	25,396	27,178	25,413	29,074	34,969	44,358	43,055	47,065	46,479
Total Current Assets	15,711	16,190	17,402	16,948	19,888	23,641	24,893	26,183	29,986	29,815
Cash & Equivalents	2,571	3,877	4,042	2,343	4,054	4,673	3,394	5,061	4,694	2,221
Short-Term Investments	7,267	7,595	9,557	10,026	10,972	12,554	13,192	13,881	16,626	18,214
Accounts Receivable	1,161	1,280	854	1,015	1,056	1,138	1,814	1,674	2,035	2,704
Other Current Assets	4,712	3,438	2,949	3,564	3,806	5,276	6,493	5,567	6,631	6,676
Plant, Property, & Equipment, net	1,384	1,505	1,584	1,735	1,955	2,371	3,073	3,221	3,030	2,532
Total Noncurrent Assets	7,583	7,701	8,192	6,730	7,231	8,957	16,392	13,651	14,049	14,132
Long-Term Investments	1,843	2,203	2,745	1,458	1,469	2,382	921	1,129	1,122	1,118
Goodwill	3,265	3,272	3,281	3,897	3,928	4,447	11,092	9,142	9,550	9,631
Other Noncurrent Operating Assets	2,475	2,226	2,166	1,375	1,834	2,128	4,379	3,380	3,377	3,383
Total Liabilities & Shareholders' Equity	24,678	25,396	27,178	25,413	29,074	34,969	44,358	43,055	47,065	46,479
Total Liabilities	14,332	14,711	17,336	15,252	17,037	21,241	28,255	27,685	30,747	30,034
Total Current Liabilities	8,152	7,822	9,406	10,077	10,929	13,394	15,331	17,178	18,872	16,939
Short-Term Debt	600	512	291	1,694	699	600	1,953	2,092	1,443	577
Accounts Payable	2,212	2,467	4,069	3,067	3,754	4,013	4,509	5,238	6,569	5,259
Current Deferred Revenue	364	280	378	283	247	318	254	286	266	260
Other Current Liabilities	4,976	4,563	4,668	5,033	6,229	8,463	8,615	9,562	10,594	10,843
Total Noncurrent Liabilities	6,180	6,889	7,930	5,175	6,108	7,847	12,924	10,507	11,875	13,095
Long-Term Debt	3,794	3,792	4,770	4,375	4,967	6,060	10,541	9,034	10,213	11,144
Other Noncurrent Operating Liabilities	2,386	3,097	3,160	800	1,141	1,787	2,383	1,473	1,662	1,951
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	10,346	10,685	9,842	10,161	12,037	13,728	16,103	15,370	16,318	16,445
Total Preferred & Common Equity	10,346	10,685	9,842	10,161	12,037	13,728	16,080	15,311	16,262	16,375
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	10,346	10,685	9,842	10,161	12,037	13,728	16,080	15,311	16,262	16,375
Common Stock	2,563	2,595	2,478	2,568	2,853	2,738	3,115	3,279	3,379	3,496
Retained Earnings	11,017	11,454	13,670	15,072	17,483	20,517	23,086	25,492	27,540	28,317
Treasury Stock	-3,292	-3,298	-6,325	-7,320	-8,455	-9,918	-10,163	-12,156	-13,658	-14,371
Accumulated Other Comprehensive Income / (Loss)	58	-66	19	-159	156	391	42	-1,304	-999	-1,067
Noncontrolling Interest	-	-	-	-	-	0.00	23	59	56	70

This table presents Humana's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025
Total Assets	50,765	43,055	54,776	56,455	55,905	47,065	50,091	50,093	50,007	46,479	50,930
Total Current Assets	33,711	26,183	37,532	38,759	38,253	29,986	32,796	32,858	32,926	29,815	34,422
Cash & Equivalents	13,558	5,061	13,735	16,214	15,148	4,694	5,910	5,501	5,116	2,221	4,250
Short-Term Investments	13,124	13,881	14,932	15,251	15,145	16,626	16,697	17,424	19,033	18,214	17,888
Accounts Receivable	1,609	1,674	3,107	1,429	1,824	2,035	3,925	4,090	2,144	2,704	4,459
Other Current Assets	5,420	5,567	5,758	5,865	6,136	6,631	6,264	5,843	6,633	6,676	7,825
Plant, Property, & Equipment, net	3,218	3,221	3,234	3,309	3,342	3,030	2,979	2,821	2,693	2,532	2,427
Total Noncurrent Assets	13,836	13,651	14,010	14,387	14,310	14,049	14,316	14,414	14,388	14,132	14,081
Long-Term Investments	1,113	1,129	1,110	1,122	1,132	1,122	1,110	1,124	1,129	1,118	1,069
Goodwill	9,096	9,142	9,320	9,539	9,540	9,550	9,563	9,567	9,590	9,631	9,631
Other Noncurrent Operating Assets	3,627	3,380	3,580	3,726	3,638	3,377	3,643	3,723	3,669	3,383	3,381
Total Liabilities & Shareholders' Equity	50,765	43,055	54,776	56,455	55,905	47,065	50,091	50,093	50,007	46,479	50,930
Total Liabilities	34,448	27,685	38,142	39,564	38,901	30,747	33,905	33,365	32,383	30,034	33,111
Total Current Liabilities	25,051	17,178	26,942	28,279	27,823	18,872	19,689	19,790	18,727	16,939	18,043
Short-Term Debt	2,799	2,092	1,867	2,022	2,245	1,443	822	1,149	1,136	577	577
Accounts Payable	6,766	5,238	7,431	8,118	7,600	6,569	6,504	6,527	5,915	5,259	5,380
Current Deferred Revenue	6,012	286	7,220	7,378	7,536	266	301	313	195	260	265
Other Current Liabilities	9,474	9,562	10,424	10,761	10,442	10,594	12,062	11,801	11,481	10,843	11,821
Total Noncurrent Liabilities	9,397	10,507	11,200	11,285	11,078	11,875	14,216	13,575	13,656	13,095	15,068
Long-Term Debt	7,798	9,034	9,743	9,722	9,483	10,213	12,390	11,746	11,886	11,144	12,729
Other Noncurrent Operating Liabilities	1,599	1,473	1,457	1,563	1,595	1,662	1,826	1,829	1,770	1,951	2,339
Commitments & Contingencies	-	0.00	-	-	-	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	16,317	15,370	16,634	16,891	17,004	16,318	16,186	16,728	17,624	16,445	17,819
Total Preferred & Common Equity	16,254	15,311	16,577	16,834	16,949	16,262	16,130	16,671	17,565	16,375	17,751
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	16,254	15,311	16,577	16,834	16,949	16,262	16,130	16,671	17,565	16,375	17,751
Common Stock	3,267	3,279	3,295	3,346	3,395	3,379	3,402	3,453	3,504	3,496	3,530
Retained Earnings	25,606	25,492	26,619	27,468	28,191	27,540	28,173	28,745	29,118	28,317	29,453
Treasury Stock	-11,152	-12,156	-12,224	-12,754	-13,134	-13,658	-14,359	-14,405	-14,404	-14,371	-14,364
Accumulated Other Comprehensive Income / (Loss)	-1,467	-1,304	-1,113	-1,226	-1,503	-999	-1,086	-1,122	-653	-1,067	-868
Noncontrolling Interest	63	59	57	57	55	56	56	57	59	70	68

This table displays calculated financial ratios and metrics derived from Humana's official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	11.94%	0.17%	-1.13%	5.85%	14.01%	18.90%	7.66%	11.81%	14.54%	10.70%
EBITDA Growth	9.00%	-28.00%	115.19%	-40.70%	51.79%	28.69%	-20.11%	9.58%	-0.44%	-30.13%
EBIT Growth	10.80%	-33.47%	144.80%	-46.48%	62.12%	32.04%	-24.64%	7.85%	-2.34%	-38.57%
NOPAT Growth	-1.33%	-44.09%	276.81%	-3.19%	-1.00%	43.50%	-24.56%	10.98%	1.10%	-35.55%
Net Income Growth	11.25%	-51.88%	298.70%	-31.25%	60.84%	24.38%	-12.86%	-4.50%	-11.35%	-51.13%
EPS Growth	14.67%	-51.78%	313.02%	-27.66%	65.30%	25.92%	-10.43%	-2.60%	-9.42%	-50.10%
Operating Cash Flow Growth	-46.35%	123.04%	109.25%	-46.36%	143.17%	6.72%	-59.89%	102.79%	-13.21%	-25.50%
Free Cash Flow Firm Growth	-123.10%	1,109.48%	119.84%	-124.89%	376.54%	8.58%	-290.54%	200.46%	-48.86%	-77.87%
Invested Capital Growth	92.88%	-57.04%	-209.67%	266.76%	-49.73%	-35.51%	1,323.62%	-42.06%	-13.90%	19.54%
Revenue Q/Q Growth	1.94%	-0.88%	0.58%	1.75%	3.39%	3.72%	2.46%	1.51%	3.93%	2.39%
EBITDA Q/Q Growth	6.09%	-24.66%	27.20%	-23.44%	3.94%	-15.61%	11.44%	0.61%	-8.77%	-6.97%
EBIT Q/Q Growth	7.74%	-29.46%	30.82%	-27.56%	4.40%	-17.52%	12.78%	0.15%	-11.06%	-9.61%
NOPAT Q/Q Growth	-5.02%	-42.88%	30.16%	12.38%	-3.17%	-13.33%	11.78%	1.85%	-13.80%	-2.16%
Net Income Q/Q Growth	-3.33%	-44.98%	31.40%	11.31%	6.16%	-18.93%	9.76%	-0.18%	-17.37%	-10.54%
EPS Q/Q Growth	-3.32%	-45.00%	31.95%	10.65%	6.74%	-18.93%	9.36%	0.14%	-17.22%	-12.99%
Operating Cash Flow Q/Q Growth	19.89%	-61.63%	-3.29%	636.54%	19.04%	-3.90%	-14.35%	-52.31%	-33.52%	181.48%
Free Cash Flow Firm Q/Q Growth	18.54%	-56.54%	-11.91%	60.01%	35.04%	-1.86%	-20.68%	-41.56%	-26.38%	114.27%
Invested Capital Q/Q Growth	-14.62%	262.02%	70.54%	256.53%	134.11%	39.11%	19.48%	829.28%	305.42%	23.19%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	18.46%	17.23%	19.10%	19.38%	17.00%	20.12%	16.69%	18.50%	16.90%	14.52%
EBITDA Margin	5.64%	4.06%	8.83%	4.95%	6.59%	7.13%	5.29%	5.18%	4.51%	2.84%
Operating Margin	4.32%	3.20%	7.93%	5.45%	4.92%	6.46%	3.79%	4.09%	3.77%	2.18%
EBIT Margin	4.82%	3.20%	7.93%	4.01%	5.70%	6.33%	4.43%	4.27%	3.64%	2.02%
Profit (Net Income) Margin	2.35%	1.13%	4.55%	2.96%	4.17%	4.36%	3.53%	3.02%	2.34%	1.03%
Tax Burden Percent	52.49%	39.56%	60.90%	81.58%	78.33%	73.20%	87.48%	78.53%	73.43%	70.54%
Interest Burden Percent	92.89%	89.14%	94.32%	90.44%	93.46%	94.20%	91.14%	89.90%	87.28%	72.28%
Effective Tax Rate	47.51%	60.44%	39.10%	18.95%	22.08%	28.41%	14.46%	21.36%	24.71%	24.00%
Return on Invested Capital (ROIC)	53.04%	31.50%	0.00%	522.34%	137.76%	359.27%	45.38%	34.12%	50.54%	32.07%
ROIC Less NNEP Spread (ROIC-NNEP)	52.47%	32.40%	0.00%	531.05%	135.40%	360.97%	42.69%	36.80%	55.98%	39.18%
Return on Net Nonoperating Assets (RNNOA)	-40.28%	-25.66%	0.00%	-505.51%	-113.37%	-333.13%	-25.70%	-16.32%	-34.86%	-24.65%
Return on Equity (ROE)	12.77%	5.84%	23.85%	16.83%	24.39%	26.14%	19.67%	17.81%	15.68%	7.41%
Cash Return on Invested Capital (CROIC)	-10.38%	111.31%	0.00%	-55.41%	203.95%	402.45%	-128.37%	87.39%	65.47%	14.26%
Operating Return on Assets (OROA)	10.86%	6.95%	16.21%	8.67%	13.57%	15.25%	9.28%	9.08%	8.60%	5.09%
Return on Assets (ROA)	5.29%	2.45%	9.31%	6.40%	9.94%	10.51%	7.40%	6.41%	5.51%	2.60%
Return on Common Equity (ROCE)	12.77%	5.84%	23.85%	16.83%	24.39%	26.14%	19.66%	17.76%	15.62%	7.38%
Return on Equity Simple (ROE_SIMPLE)	12.33%	5.75%	24.87%	16.56%	22.49%	24.53%	18.25%	18.30%	15.27%	7.41%
Net Operating Profit after Tax (NOPAT)	1,232	689	2,595	2,512	2,487	3,569	2,693	2,988	3,021	1,947
NOPAT Margin	2.27%	1.27%	4.83%	4.41%	3.83%	4.63%	3.24%	3.22%	2.84%	1.65%
Net Nonoperating Expense Percent (NNEP)	0.57%	-0.90%	-1.43%	-8.71%	2.36%	-1.70%	2.69%	-2.67%	-5.45%	-7.11%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	11.28%	10.80%	6.91%
Cost of Revenue to Revenue	81.54%	82.77%	80.90%	80.62%	83.00%	79.88%	83.31%	81.50%	83.10%	85.48%
SG&A Expenses to Revenue	13.44%	13.19%	12.21%	13.22%	11.38%	13.03%	12.18%	13.64%	12.40%	11.63%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	14.13%	14.03%	11.18%	13.93%	12.08%	13.66%	12.90%	14.41%	13.13%	12.34%
Earnings before Interest and Taxes (EBIT)	2,617	1,741	4,262	2,281	3,698	4,883	3,680	3,969	3,876	2,381
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	3,064	2,206	4,747	2,815	4,273	5,499	4,393	4,814	4,793	3,349
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.41	2.69	3.44	3.72	3.90	3.85	3.64	4.16	3.43	1.87
Price to Tangible Book Value (P/TBV)	3.52	3.88	5.15	6.03	5.79	5.70	11.73	10.32	8.30	4.53
Price to Revenue (P/Rev)	0.46	0.53	0.63	0.66	0.72	0.69	0.70	0.69	0.52	0.26
Price to Earnings (P/E)	19.52	46.87	13.81	22.43	17.36	15.72	19.94	22.68	22.39	25.31
Dividend Yield	0.68%	0.60%	0.80%	0.73%	0.62%	0.63%	0.62%	0.63%	0.78%	1.40%
Earnings Yield	5.12%	2.13%	7.24%	4.46%	5.76%	6.36%	5.01%	4.41%	4.47%	3.95%
Enterprise Value to Invested Capital (EV/IC)	5.76	14.77	0.00	12.48	29.93	51.31	4.82	8.52	8.13	3.14
Enterprise Value to Revenue (EV/Rev)	0.32	0.36	0.42	0.53	0.56	0.52	0.64	0.59	0.42	0.18
Enterprise Value to EBITDA (EV/EBITDA)	5.75	8.80	4.75	10.65	8.46	7.27	12.18	11.37	9.39	6.21
Enterprise Value to EBIT (EV/EBIT)	6.73	11.15	5.29	13.15	9.78	8.19	14.54	13.79	11.61	8.73
Enterprise Value to NOPAT (EV/NOPAT)	14.31	28.18	8.68	11.94	14.54	11.20	19.87	18.32	14.89	10.68
Enterprise Value to Operating Cash Flow (EV/OCF)	20.30	10.03	5.56	13.80	6.84	7.09	23.65	11.94	11.30	7.01
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	7.97	4.21	0.00	9.82	10.00	0.00	7.15	11.50	24.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.42	0.40	0.51	0.60	0.47	0.49	0.78	0.72	0.71	0.71
Long-Term Debt to Equity	0.37	0.35	0.48	0.43	0.41	0.44	0.65	0.59	0.63	0.68
Financial Leverage	-0.77	-0.79	-1.01	-0.95	-0.84	-0.92	-0.60	-0.44	-0.62	-0.63
Leverage Ratio	2.41	2.38	2.56	2.63	2.45	2.49	2.66	2.78	2.84	2.86
Compound Leverage Factor	2.24	2.12	2.42	2.38	2.29	2.34	2.42	2.50	2.48	2.06
Debt to Total Capital	29.81%	28.71%	33.96%	37.39%	32.01%	32.67%	43.69%	41.99%	41.67%	41.61%
Short-Term Debt to Total Capital	4.07%	3.42%	1.95%	10.44%	3.95%	2.94%	6.83%	7.90%	5.16%	2.05%
Long-Term Debt to Total Capital	25.74%	25.30%	32.01%	26.96%	28.06%	29.72%	36.86%	34.10%	36.51%	39.57%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.08%	0.22%	0.20%	0.25%
Common Equity to Total Capital	70.19%	71.29%	66.04%	62.61%	67.99%	67.33%	56.23%	57.79%	58.13%	58.14%
Debt to EBITDA	1.43	1.95	1.07	2.16	1.33	1.21	2.84	2.31	2.43	3.50
Net Debt to EBITDA	-2.38	-4.25	-2.38	-2.76	-2.53	-2.35	-1.14	-1.86	-2.25	-2.94
Long-Term Debt to EBITDA	1.24	1.72	1.00	1.55	1.16	1.10	2.40	1.88	2.13	3.33
Debt to NOPAT	3.57	6.25	1.95	2.42	2.28	1.87	4.64	3.72	3.86	6.02
Net Debt to NOPAT	-5.92	-13.61	-4.35	-3.09	-4.35	-3.63	-1.86	-2.99	-3.57	-5.05
Long-Term Debt to NOPAT	3.08	5.51	1.84	1.74	2.00	1.70	3.91	3.02	3.38	5.72
Altman Z-Score	4.59	4.57	4.72	5.18	5.52	5.34	4.38	4.92	4.72	4.50
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.08%	0.26%	0.36%	0.38%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.93	2.07	1.85	1.68	1.82	1.77	1.62	1.52	1.59	1.76
Quick Ratio	1.35	1.63	1.54	1.33	1.47	1.37	1.20	1.20	1.24	1.37
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-241	2,434	5,350	-1,332	3,682	3,998	-7,618	7,653	3,914	866
Operating Cash Flow to CapEx	166.28%	367.36%	773.09%	355.07%	717.93%	584.96%	171.88%	409.55%	501.39%	522.18%
Free Cash Flow to Firm to Interest Expense	-1.30	12.88	22.11	-6.11	15.22	14.13	-23.37	19.09	7.94	1.31
Operating Cash Flow to Interest Expense	4.67	10.24	16.74	9.97	21.83	19.93	6.94	11.44	8.08	4.49
Operating Cash Flow Less CapEx to Interest Expense	1.86	7.46	14.57	7.16	18.79	16.52	2.90	8.65	6.46	3.63
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	2.25	2.17	2.05	2.16	2.38	2.41	2.09	2.12	2.36	2.52
Accounts Receivable Turnover	49.04	44.55	50.39	60.90	62.66	70.33	56.28	53.25	57.36	49.70
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	41.57	37.65	34.81	34.29	35.17	35.67	30.52	29.51	34.03	42.34
Accounts Payable Turnover	20.56	19.24	13.31	12.86	15.79	15.87	16.24	15.53	14.97	17.02
Days Sales Outstanding (DSO)	7.44	8.19	7.24	5.99	5.82	5.19	6.49	6.85	6.36	7.34
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	17.76	18.97	27.42	28.38	23.11	23.00	22.48	23.50	24.38	21.44
Cash Conversion Cycle (CCC)	-10.31	-10.78	-20.18	-22.39	-17.29	-17.81	-15.99	-16.65	-18.01	-14.10
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	3,059	1,314	-1,441	2,403	1,208	779	11,090	6,425	5,532	6,613
Invested Capital Turnover	23.38	24.87	-846.72	118.32	35.94	77.66	14.00	10.60	17.79	19.39
Increase / (Decrease) in Invested Capital	1,473	-1,745	-2,755	3,844	-1,195	-429	10,311	-4,665	-893	1,081
Enterprise Value (EV)	17,624	19,409	22,525	29,991	36,154	39,971	53,499	54,749	45,001	20,788
Market Capitalization	24,911	28,780	33,808	37,749	46,983	52,920	58,489	63,635	55,731	30,550
Book Value per Share	$69.80	$71.66	$68.89	$74.07	$90.90	$103.73	$125.10	$120.94	$132.09	$135.99
Tangible Book Value per Share	$47.77	$49.72	$45.93	$45.66	$61.23	$70.13	$38.81	$48.73	$54.52	$56.01
Total Capital	14,740	14,989	14,903	16,230	17,703	20,388	28,597	26,496	27,974	28,166
Total Debt	4,394	4,304	5,061	6,069	5,666	6,660	12,494	11,126	11,656	11,721
Total Long-Term Debt	3,794	3,792	4,770	4,375	4,967	6,060	10,541	9,034	10,213	11,144
Net Debt	-7,287	-9,371	-11,283	-7,758	-10,829	-12,949	-5,013	-8,945	-10,786	-9,832
Capital Expenditures (CapEx)	522	527	524	612	736	964	1,316	1,120	794	568
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-1,679	-2,592	-5,312	-3,804	-5,368	-6,380	-5,071	-7,845	-8,763	-6,982
Debt-free Net Working Capital (DFNWC)	8,159	8,880	8,287	8,565	9,658	10,847	11,515	11,097	12,557	13,453
Net Working Capital (NWC)	7,559	8,368	7,996	6,871	8,959	10,247	9,562	9,005	11,114	12,876
Net Nonoperating Expense (NNE)	-44	75	147	829	-220	202	-241	186	537	733
Net Nonoperating Obligations (NNO)	-7,287	-9,371	-11,283	-7,758	-10,829	-12,949	-5,013	-8,945	-10,786	-9,832
Total Depreciation and Amortization (D&A)	447	465	485	534	575	616	713	845	917	968
Debt-free, Cash-free Net Working Capital to Revenue	-3.09%	-4.77%	-9.88%	-6.68%	-8.27%	-8.27%	-6.10%	-8.45%	-8.24%	-5.93%
Debt-free Net Working Capital to Revenue	15.03%	16.33%	15.41%	15.05%	14.88%	14.06%	13.86%	11.95%	11.80%	11.42%
Net Working Capital to Revenue	13.92%	15.39%	14.87%	12.07%	13.81%	13.28%	11.51%	9.70%	10.45%	10.93%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$8.54	$4.11	$16.94	$12.24	$20.20	$25.47	$22.79	$22.20	$20.09	$10.01
Adjusted Weighted Average Basic Shares Outstanding	148.30M	149.32M	137.68M	135.57M	132.11M	128.86M	126.63M	124.97M	120.65M	120.64M
Adjusted Diluted Earnings per Share	$8.44	$4.07	$16.81	$12.16	$20.10	$25.31	$22.67	$22.08	$20.00	$9.98
Adjusted Weighted Average Diluted Shares Outstanding	148.30M	149.32M	137.68M	135.57M	132.11M	128.86M	126.63M	124.97M	120.65M	120.64M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	148.30M	149.32M	137.68M	135.57M	132.11M	128.86M	126.63M	124.97M	120.65M	120.64M
Normalized Net Operating Profit after Tax (NOPAT)	1,232	1,219	2,595	2,512	2,487	3,569	2,693	2,988	3,021	1,947
Normalized NOPAT Margin	2.27%	2.24%	4.83%	4.41%	3.83%	4.63%	3.24%	3.22%	2.84%	1.65%
Pre Tax Income Margin	4.48%	2.85%	7.48%	3.62%	5.33%	5.96%	4.04%	3.84%	3.18%	1.46%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	14.07	9.21	17.61	10.46	15.28	17.25	11.29	9.90	7.86	3.61
NOPAT to Interest Expense	6.62	3.64	10.72	11.53	10.28	12.61	8.26	7.45	6.13	2.95
EBIT Less CapEx to Interest Expense	11.26	6.42	15.45	7.66	12.24	13.85	7.25	7.10	6.25	2.75
NOPAT Less CapEx to Interest Expense	3.82	0.86	8.56	8.72	7.24	9.21	4.22	4.66	4.52	2.09
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	13.48%	28.83%	8.99%	15.75%	10.75%	9.59%	12.07%	13.99%	17.35%	35.50%
Augmented Payout Ratio	43.65%	45.77%	146.45%	80.51%	50.28%	63.65%	14.76%	88.79%	80.68%	102.80%

This table displays calculated financial ratios and metrics derived from Humana's official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	10.16%	6.58%	11.56%	13.04%	15.90%	17.93%	10.73%	10.44%	11.26%	10.40%	8.45%
EBITDA Growth	-15.33%	12.89%	28.38%	12.29%	-10.29%	-181.50%	-27.25%	-17.35%	-26.54%	-121.26%	46.01%
EBIT Growth	-18.85%	19.35%	31.83%	13.00%	-13.37%	-1,302.70%	-32.08%	-21.42%	-32.34%	-56.85%	57.80%
NOPAT Growth	84.78%	103.28%	35.45%	46.05%	-14.00%	-380.65%	-30.42%	-21.41%	-40.02%	-56.03%	64.56%
Net Income Growth	-22.08%	-38.46%	33.12%	37.16%	-30.43%	-2,900.00%	-40.31%	-29.08%	-42.17%	-26.48%	68.07%
EPS Growth	-20.69%	27.27%	35.39%	39.78%	-28.54%	-5,200.00%	-38.10%	-26.63%	-40.69%	-35.14%	68.58%
Operating Cash Flow Growth	198.17%	-5,240.63%	2,114.24%	231.18%	-85.19%	-39.15%	-93.67%	-61.81%	48.40%	92.60%	-21.75%
Free Cash Flow Firm Growth	238.06%	146.28%	285.65%	486.03%	-75.65%	-86.33%	-149.48%	-175.09%	-374.27%	-324.99%	88.76%
Invested Capital Growth	-109.49%	-42.06%	-115.59%	-160.94%	-205.68%	-13.90%	470.58%	241.04%	299.33%	19.54%	39.38%
Revenue Q/Q Growth	-3.65%	-1.58%	19.18%	0.02%	-1.21%	0.15%	11.90%	-0.24%	-0.48%	-0.63%	9.92%
EBITDA Q/Q Growth	12.64%	-84.25%	665.75%	-17.33%	-10.01%	-114.31%	783.57%	-6.08%	-20.02%	-143.09%	551.09%
EBIT Q/Q Growth	14.39%	-97.36%	4,567.57%	-19.98%	-12.30%	-136.72%	363.60%	-7.42%	-24.49%	-185.12%	365.19%
NOPAT Q/Q Growth	42.88%	-91.93%	1,439.91%	-17.77%	-15.86%	-126.34%	481.79%	-7.12%	-35.79%	-168.53%	502.64%
Net Income Q/Q Growth	71.16%	-101.51%	6,977.78%	-22.78%	-13.18%	-165.06%	236.85%	-8.25%	-29.20%	-242.29%	281.84%
EPS Q/Q Growth	71.35%	-100.85%	12,437.50%	-22.39%	-12.40%	-163.19%	244.10%	-8.02%	-29.18%	-243.97%	279.76%
Operating Cash Flow Q/Q Growth	781.44%	-160.65%	230.43%	-52.50%	-60.58%	-669.81%	105.93%	186.76%	53.17%	-128.42%	162.69%
Free Cash Flow Firm Q/Q Growth	476.07%	-57.72%	167.28%	-9.17%	-76.28%	-76.27%	-1,067.66%	-37.85%	13.34%	80.54%	51.64%
Invested Capital Q/Q Growth	-113.59%	829.28%	-123.86%	-157.80%	31.86%	305.42%	2.69%	-1.88%	-3.70%	23.19%	19.73%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	19.36%	17.19%	18.26%	17.71%	17.70%	13.91%	15.15%	15.24%	14.55%	13.12%	17.37%
EBITDA Margin	7.07%	1.13%	7.27%	6.01%	5.48%	-0.78%	4.78%	4.50%	3.62%	-1.57%	6.43%
Operating Margin	5.14%	0.55%	6.43%	5.37%	4.56%	-1.32%	4.17%	3.86%	2.48%	-1.86%	6.27%
EBIT Margin	6.14%	0.16%	6.46%	5.17%	4.59%	-1.68%	3.96%	3.68%	2.79%	-2.39%	5.76%
Profit (Net Income) Margin	5.23%	-0.08%	4.63%	3.57%	3.14%	-2.04%	2.50%	2.30%	1.63%	-2.34%	3.87%
Tax Burden Percent	91.98%	25.35%	76.70%	75.75%	75.59%	91.37%	72.88%	73.86%	73.73%	79.23%	73.45%
Interest Burden Percent	92.71%	-191.89%	93.46%	91.32%	90.59%	132.81%	86.45%	84.53%	79.39%	123.50%	91.36%
Effective Tax Rate	8.25%	0.00%	22.24%	23.45%	23.32%	0.00%	24.75%	24.29%	23.81%	0.00%	24.01%
Return on Invested Capital (ROIC)	102.72%	4.10%	115.22%	320.35%	0.00%	-16.38%	165.44%	403.97%	162.24%	-25.23%	84.30%
ROIC Less NNEP Spread (ROIC-NNEP)	101.75%	5.60%	116.05%	321.31%	0.00%	-13.38%	166.77%	405.14%	162.71%	-22.29%	87.12%
Return on Net Nonoperating Assets (RNNOA)	-75.51%	-2.49%	-85.94%	-296.19%	0.00%	8.33%	-145.69%	-385.59%	-150.14%	14.03%	-52.28%
Return on Equity (ROE)	27.21%	1.62%	29.28%	24.16%	18.04%	-8.05%	19.75%	18.38%	12.10%	-11.20%	32.01%
Cash Return on Invested Capital (CROIC)	0.00%	87.39%	0.00%	0.00%	0.00%	65.47%	-81.10%	-128.45%	-113.09%	14.26%	4.59%
Operating Return on Assets (OROA)	11.68%	0.35%	12.22%	9.88%	8.80%	-3.97%	8.25%	7.73%	6.06%	-6.02%	13.72%
Return on Assets (ROA)	9.96%	-0.17%	8.76%	6.83%	6.03%	-4.82%	5.20%	4.83%	3.55%	-5.89%	9.21%
Return on Common Equity (ROCE)	27.16%	1.61%	29.21%	24.10%	17.98%	-8.02%	19.68%	18.32%	12.06%	-11.16%	31.90%
Return on Equity Simple (ROE_SIMPLE)	17.27%	0.00%	18.76%	20.01%	17.74%	0.00%	12.31%	10.24%	7.73%	0.00%	9.67%
Net Operating Profit after Tax (NOPAT)	1,075	87	1,337	1,099	925	-244	930	864	555	-380	1,530
NOPAT Margin	4.72%	0.39%	5.00%	4.11%	3.50%	-0.92%	3.14%	2.92%	1.89%	-1.30%	4.77%
Net Nonoperating Expense Percent (NNEP)	0.97%	-1.50%	-0.83%	-0.96%	-0.51%	-3.00%	-1.33%	-1.16%	-0.47%	-2.94%	-2.83%
Return On Investment Capital (ROIC_SIMPLE)	-	0.33%	-	-	-	-0.87%	-	-	-	-1.35%	4.92%
Cost of Revenue to Revenue	80.64%	82.81%	81.74%	82.29%	82.30%	86.09%	84.85%	84.76%	85.45%	86.88%	82.63%
SG&A Expenses to Revenue	13.43%	15.83%	11.14%	11.63%	12.38%	14.46%	10.27%	10.66%	11.36%	14.26%	10.53%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	14.22%	16.64%	11.84%	12.35%	13.14%	15.22%	10.98%	11.37%	12.07%	14.98%	11.10%
Earnings before Interest and Taxes (EBIT)	1,399	37	1,727	1,382	1,212	-445	1,173	1,086	820	-698	1,851
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	1,613	254	1,945	1,608	1,447	-207	1,415	1,329	1,063	-458	2,066
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	3.72	4.16	3.62	3.29	3.52	3.43	2.64	2.70	2.17	1.87	1.80
Price to Tangible Book Value (P/TBV)	8.46	10.32	8.27	7.59	8.06	8.30	6.48	6.34	4.78	4.53	3.93
Price to Revenue (P/Rev)	0.66	0.69	0.63	0.56	0.58	0.52	0.39	0.40	0.33	0.26	0.27
Price to Earnings (P/E)	21.57	22.68	19.27	16.39	19.80	22.39	21.39	26.32	28.06	25.31	18.67
Dividend Yield	0.64%	0.63%	0.68%	0.75%	0.71%	0.78%	1.02%	0.95%	1.12%	1.40%	1.34%
Earnings Yield	4.64%	4.41%	5.19%	6.10%	5.05%	4.47%	4.68%	3.80%	3.56%	3.95%	5.36%
Enterprise Value to Invested Capital (EV/IC)	0.00	8.52	0.00	0.00	0.00	8.13	5.66	6.09	4.83	3.14	2.79
Enterprise Value to Revenue (EV/Rev)	0.47	0.59	0.44	0.35	0.39	0.42	0.29	0.30	0.23	0.18	0.18
Enterprise Value to EBITDA (EV/EBITDA)	9.07	11.37	7.99	6.38	7.62	9.39	7.54	8.52	7.21	6.21	5.52
Enterprise Value to EBIT (EV/EBIT)	10.95	13.79	9.56	7.61	9.19	11.61	9.67	11.21	9.85	8.73	7.22
Enterprise Value to NOPAT (EV/NOPAT)	14.79	18.32	12.55	9.38	11.43	14.89	12.33	14.34	13.03	10.68	8.67
Enterprise Value to Operating Cash Flow (EV/OCF)	4.51	11.94	3.82	2.62	6.69	11.30	0.00	0.00	0.00	7.01	7.69
Enterprise Value to Free Cash Flow (EV/FCFF)	3.31	7.15	2.85	2.45	7.53	11.50	0.00	0.00	0.00	24.00	70.83
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.65	0.72	0.70	0.70	0.69	0.71	0.82	0.77	0.74	0.71	0.75
Long-Term Debt to Equity	0.48	0.59	0.59	0.58	0.56	0.63	0.77	0.70	0.67	0.68	0.71
Financial Leverage	-0.74	-0.44	-0.74	-0.92	-1.11	-0.62	-0.87	-0.95	-0.92	-0.63	-0.60
Leverage Ratio	2.95	2.78	3.16	3.19	3.20	2.84	3.20	3.17	3.06	2.86	2.97
Compound Leverage Factor	2.73	-5.33	2.95	2.91	2.90	3.78	2.76	2.68	2.43	3.53	2.71
Debt to Total Capital	39.37%	41.99%	41.11%	41.01%	40.82%	41.67%	44.94%	43.53%	42.49%	41.61%	42.75%
Short-Term Debt to Total Capital	10.40%	7.90%	6.61%	7.06%	7.81%	5.16%	2.80%	3.88%	3.71%	2.05%	1.85%
Long-Term Debt to Total Capital	28.97%	34.10%	34.50%	33.95%	33.01%	36.51%	42.15%	39.65%	38.78%	39.57%	40.90%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.23%	0.22%	0.20%	0.20%	0.19%	0.20%	0.19%	0.19%	0.19%	0.25%	0.22%
Common Equity to Total Capital	60.39%	57.79%	58.69%	58.79%	58.99%	58.13%	54.87%	56.28%	57.32%	58.14%	57.03%
Debt to EBITDA	2.21	2.31	2.21	2.17	2.23	2.43	3.10	3.24	3.62	3.50	3.33
Net Debt to EBITDA	-3.59	-1.86	-3.46	-3.85	-3.75	-2.25	-2.46	-2.80	-3.40	-2.94	-2.48
Long-Term Debt to EBITDA	1.63	1.88	1.86	1.79	1.80	2.13	2.91	2.95	3.30	3.33	3.18
Debt to NOPAT	3.61	3.72	3.48	3.19	3.35	3.86	5.07	5.45	6.54	6.02	5.22
Net Debt to NOPAT	-5.86	-2.99	-5.44	-5.65	-5.62	-3.57	-4.03	-4.71	-6.16	-5.05	-3.88
Long-Term Debt to NOPAT	2.66	3.02	2.92	2.64	2.71	3.38	4.75	4.96	5.97	5.72	4.99
Altman Z-Score	3.86	4.62	3.71	3.57	3.75	4.42	4.11	4.23	4.22	4.28	4.26
Noncontrolling Interest Sharing Ratio	0.19%	0.26%	0.25%	0.24%	0.35%	0.36%	0.34%	0.34%	0.33%	0.38%	0.36%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.35	1.52	1.39	1.37	1.37	1.59	1.67	1.66	1.76	1.76	1.91
Quick Ratio	1.13	1.20	1.18	1.16	1.15	1.24	1.35	1.37	1.40	1.37	1.47
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	11,238	4,752	12,701	11,536	2,737	649	-6,284	-8,662	-7,506	-1,461	-707
Operating Cash Flow to CapEx	2,935.07%	-1,864.36%	2,998.65%	1,203.03%	535.04%	-2,520.85%	238.98%	1,064.04%	1,429.23%	-342.86%	348.42%
Free Cash Flow to Firm to Interest Expense	110.18	44.00	112.40	96.13	24.01	4.45	-39.52	-51.56	-44.42	-8.91	-4.42
Operating Cash Flow to Interest Expense	82.87	-47.47	59.18	26.47	10.98	-48.86	2.66	7.22	10.99	-3.22	2.07
Operating Cash Flow Less CapEx to Interest Expense	80.05	-50.02	57.20	24.27	8.93	-50.80	1.55	6.54	10.22	-4.16	1.48
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	1.90	2.12	1.89	1.91	1.92	2.36	2.08	2.10	2.17	2.52	2.38
Accounts Receivable Turnover	52.46	53.25	30.45	41.15	59.63	57.36	31.07	40.60	57.97	49.70	28.69
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	29.92	29.51	29.78	30.71	31.20	34.03	35.17	36.55	38.11	42.34	44.49
Accounts Payable Turnover	12.72	15.53	11.73	11.63	11.72	14.97	13.16	12.93	14.51	17.02	17.18
Days Sales Outstanding (DSO)	6.96	6.85	11.99	8.87	6.12	6.36	11.75	8.99	6.30	7.34	12.72
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	28.70	23.50	31.13	31.39	31.14	24.38	27.75	28.23	25.15	21.44	21.25
Cash Conversion Cycle (CCC)	-21.74	-16.65	-19.14	-22.52	-25.02	-18.01	-16.00	-19.24	-18.86	-14.10	-8.52
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	-881	6,425	-1,533	-3,952	-2,693	5,532	5,681	5,574	5,368	6,613	7,918
Invested Capital Turnover	21.78	10.60	23.05	77.95	-57.28	17.79	52.67	138.15	85.99	19.39	17.69
Increase / (Decrease) in Invested Capital	-10,163	-4,665	-11,364	-10,437	-1,812	-893	7,214	9,526	8,061	1,081	2,237
Enterprise Value (EV)	43,409	54,749	41,913	34,594	40,058	45,001	32,132	33,928	25,939	20,788	22,090
Market Capitalization	60,544	63,635	60,023	55,380	59,700	55,731	42,581	45,025	38,136	30,550	31,923
Book Value per Share	$128.44	$120.94	$132.64	$134.73	$136.79	$132.09	$133.86	$138.35	$145.89	$135.99	$147.13
Tangible Book Value per Share	$56.56	$48.73	$58.07	$58.39	$59.80	$54.52	$54.50	$58.95	$66.24	$56.01	$67.31
Total Capital	26,914	26,496	28,244	28,635	28,732	27,974	29,398	29,623	30,646	28,166	31,125
Total Debt	10,597	11,126	11,610	11,744	11,728	11,656	13,212	12,895	13,022	11,721	13,306
Total Long-Term Debt	7,798	9,034	9,743	9,722	9,483	10,213	12,390	11,746	11,886	11,144	12,729
Net Debt	-17,198	-8,945	-18,167	-20,843	-19,697	-10,786	-10,505	-11,154	-12,256	-9,832	-9,901
Capital Expenditures (CapEx)	288	275	223	264	234	283	177	114	130	154	95
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-15,223	-7,845	-16,210	-18,963	-17,618	-8,763	-8,678	-8,708	-8,814	-6,982	-5,182
Debt-free Net Working Capital (DFNWC)	11,459	11,097	12,457	12,502	12,675	12,557	13,929	14,217	15,335	13,453	16,956
Net Working Capital (NWC)	8,660	9,005	10,590	10,480	10,430	11,114	13,107	13,068	14,199	12,876	16,379
Net Nonoperating Expense (NNE)	-118	105	99	143	95	296	191	186	75	303	288
Net Nonoperating Obligations (NNO)	-17,198	-8,945	-18,167	-20,843	-19,697	-10,786	-10,505	-11,154	-12,256	-9,832	-9,901
Total Depreciation and Amortization (D&A)	214	217	218	226	235	238	242	243	243	240	215
Debt-free, Cash-free Net Working Capital to Revenue	-16.64%	-8.45%	-16.95%	-19.21%	-17.21%	-8.24%	-7.94%	-7.77%	-7.66%	-5.93%	-4.31%
Debt-free Net Working Capital to Revenue	12.53%	11.95%	13.02%	12.66%	12.38%	11.80%	12.75%	12.69%	13.33%	11.42%	14.10%
Net Working Capital to Revenue	9.47%	9.70%	11.07%	10.62%	10.19%	10.45%	12.00%	11.66%	12.35%	10.93%	13.62%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$9.45	($0.07)	$9.91	$7.70	$6.74	($4.26)	$6.13	$5.63	$3.99	($5.74)	$10.31
Adjusted Weighted Average Basic Shares Outstanding	126.60M	124.97M	124.94M	123.91M	123.11M	120.65M	120.50M	120.40M	120.41M	120.64M	120.69M
Adjusted Diluted Earnings per Share	$9.39	($0.08)	$9.87	$7.66	$6.71	($4.24)	$6.11	$5.62	$3.98	($5.73)	$10.30
Adjusted Weighted Average Diluted Shares Outstanding	126.60M	124.97M	124.94M	123.91M	123.11M	120.65M	120.50M	120.40M	120.41M	120.64M	120.69M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	126.60M	124.97M	124.94M	123.91M	123.11M	120.65M	120.50M	120.40M	120.41M	120.64M	120.69M
Normalized Net Operating Profit after Tax (NOPAT)	1,075	87	1,337	1,099	925	-244	930	864	555	-380	1,530
Normalized NOPAT Margin	4.72%	0.39%	5.00%	4.11%	3.50%	-0.92%	3.14%	2.92%	1.89%	-1.30%	4.77%
Pre Tax Income Margin	5.69%	-0.32%	6.04%	4.72%	4.16%	-2.23%	3.42%	3.11%	2.21%	-2.95%	5.27%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	13.72	0.34	15.28	11.52	10.63	-3.05	7.38	6.46	4.85	-4.26	11.57
NOPAT to Interest Expense	10.54	0.80	11.83	9.16	8.11	-1.67	5.85	5.14	3.28	-2.32	9.57
EBIT Less CapEx to Interest Expense	10.89	-2.20	13.31	9.32	8.58	-4.99	6.26	5.79	4.08	-5.20	10.98
NOPAT Less CapEx to Interest Expense	7.72	-1.74	9.86	6.96	6.06	-3.61	4.74	4.46	2.51	-3.26	8.97
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	13.61%	13.99%	12.89%	12.23%	14.01%	17.35%	22.17%	25.54%	31.98%	35.50%	25.04%
Augmented Payout Ratio	51.91%	88.79%	50.39%	62.42%	82.73%	80.68%	132.80%	126.07%	130.66%	102.80%	31.39%

Frequently Asked Questions About Humana's Financials

When does Humana's financial year end?

According to the most recent income statement we have on file, Humana's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Humana's net income changed over the last 9 years?

Humana's net income appears to be on an upward trend, with a most recent value of $1.21 billion in 2024, falling from $1.28 billion in 2015. The previous period was $2.48 billion in 2023. See where experts think Humana is headed by visiting Humana's forecast page.

What is Humana's operating income?

Humana's total operating income in 2024 was $2.56 billion, based on the following breakdown:

Total Gross Profit: $17.10 billion
Total Operating Expenses: $14.54 billion

How has Humana revenue changed over the last 9 years?

Over the last 9 years, Humana's total revenue changed from $54.29 billion in 2015 to $117.76 billion in 2024, a change of 116.9%.

How much debt does Humana have?

Humana's total liabilities were at $30.03 billion at the end of 2024, a 2.3% decrease from 2023, and a 109.6% increase since 2015.

How much cash does Humana have?

In the past 9 years, Humana's cash and equivalents has ranged from $2.22 billion in 2024 to $5.06 billion in 2022, and is currently $2.22 billion as of their latest financial filing in 2024.

How has Humana's book value per share changed over the last 9 years?

Over the last 9 years, Humana's book value per share changed from 69.80 in 2015 to 135.99 in 2024, a change of 94.8%.

Related Companies

This page (NYSE:HUM) was last updated on 5/6/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Humana (HUM) Financials

Frequently Asked Questions About Humana's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Humana (HUM) Financials

Annual Income Statements for Humana

Quarterly Income Statements for Humana

Annual Cash Flow Statements for Humana

Quarterly Cash Flow Statements for Humana

Annual Balance Sheets for Humana

Quarterly Balance Sheets for Humana

Annual Metrics and Ratios for Humana

Quarterly Metrics and Ratios for Humana

Frequently Asked Questions About Humana's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools